Patents by Inventor Jeffrey Zuber

Jeffrey Zuber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240132886
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component 9 (C9) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a C9 gene and to methods of preventing and treating a C9-associated disorder, e.g., paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Type: Application
    Filed: June 29, 2023
    Publication date: April 25, 2024
    Inventors: Elane Fishilevich, Anna Borodovsky, Jeffrey Zuber
  • GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240132895
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a GSK3? gene, as well as methods of inhibiting expression of a GSK3? gene and methods of treating subjects having a GSK3? associated neurodegenerative disease or disorder, e.g., Fragile X Syndrome, using such dsRNAi agents and compositions.
    Type: Application
    Filed: September 7, 2023
    Publication date: April 25, 2024
    Inventors: William Cantley, Jeffrey Zuber, Adam Castoreno, Charalambos Kaittanis
  • iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP)
    Publication number: 20240117349
    Abstract: The disclosure relates to compositions and methods for treating amyloid precursor protein (APP)-associated diseases and disorders. More particularly, the disclosure relates to APP-targeting RNAi agents and methods, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as cerebral amyloid angiopathy (CAA) and early onset familial Alzheimer disease (EOFAD or eFAD), using such dsRNAi agents and compositions.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 11, 2024
    Inventors: Jeffrey Zuber, Adam Castoreno
  • COAGULATION FACTOR X (F10) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240117348
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the Coagulation Factor X (F10) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an F10 gene and to methods of treating or preventing an F10-associated disease, e.g., a disorder associated with thrombosis, in a subject.
    Type: Application
    Filed: June 6, 2023
    Publication date: April 11, 2024
    Inventors: Mark Keating, Jeffrey Zuber
  • MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230416736
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the mucin 5B (MUC5B) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a MUC5B gene and to methods of treating or preventing a MUC5B-associated disease, such as a lung disease, e.g., cystic fibrosis, chronic obstructive pulmonary disease (COPD), and/or pulmonary fibrosis, e.g., idiopathic pulmonary fibrosis (IPF), in a subject.
    Type: Application
    Filed: April 19, 2023
    Publication date: December 28, 2023
    Inventors: Leila Noetzli, Margaret Parker, James D. McIninch, Mark K. Schlegel, Adam Castoreno, Jeffrey Zuber
  • MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230203486
    Abstract: The disclosure relates to double stranded ribonucleic acid interference (dsRNAi) agents and compositions targeting a microtubule-associated protein tau (MAPT) gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated disease or disorder, e.g., Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, or other tauopathies, using such dsRNAi agents and compositions.
    Type: Application
    Filed: March 30, 2021
    Publication date: June 29, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: MANGALA MEENAKSHI SOUNDARAPANDIAN, JAMES D. MCININCH, ELANE FISHILEVICH, ADAM CASTORENO, CHARALAMBOS KAITTANIS, MARK K. SCHLEGEL, JONATHAN EDWARD FARLEY, JEFFREY ZUBER
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230133637
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.
    Type: Application
    Filed: September 1, 2022
    Publication date: May 4, 2023
    Inventors: Lucas D. BonDurant, Mark K. Schlegel, Jeffrey Zuber, Lauren Blair Woods, Tyler Chickering
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 11613751
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 28, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Lucas D. BonDurant, Mark K. Schlegel, Jeffrey Zuber, Lauren Blair Woods, Tyler Chickering
  • HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220380762
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a Huntingtin (HTT) gene, e.g., exon 1 of an HTT gene, as well as methods of inhibiting expression of an HTT gene and methods of treating subjects having an HTT-associated disease or disorder, e.g., Huntington's disease, using such dsRNAi agents and compositions.
    Type: Application
    Filed: April 28, 2022
    Publication date: December 1, 2022
    Inventors: Mangala Meenakshi Soundarapandian, James D. McIninch, Bret Lee Bostwick, Mark K. Schlegel, Adam Castoreno, Jeffrey Zuber
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220290153
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.
    Type: Application
    Filed: March 8, 2022
    Publication date: September 15, 2022
    Inventors: Lucas D. BonDurant, Mark K. Schlegel, Jeffrey Zuber, Lauren Blair Woods, Tyler Chickering